Literature DB >> 24511001

Accumulation of FGF9 in prostate cancer correlates with epithelial-to-mesenchymal transition and induction of VEGF-A expression.

Jun Teishima1, Shigeki Yano, Koichi Shoji, Tetsutaro Hayashi, Keisuke Goto, Hiroyuki Kitano, Kiyotaka Oka, Hirotaka Nagamatsu, Akio Matsubara.   

Abstract

AIM: The aim of the present study was to investigate the molecular mechanism of fibroblast growth factor (FGF)-9 in prostate cancer cells.
MATERIALS AND METHODS: Expression of vascular endothelial growth factor (VEGF)s and cadherins in LNCaP cells by incubation with FGF9 was assessed by western blot analysis. Tissues obtained during a radical prostatectomy in 88 patients were immunohistochemically-stained using anti-FGF9, anti-cadherin, and anti-VEGF antibodies.
RESULTS: Expression of N-cadherin and VEGF-A were induced in LNCaP cells incubated in FGF9-containing medium. The biochemical relapse-free survival rate in cases with FGF9, N-cadherin and VEGF-A-positive cells was significantly lower than the rate in cases where positive cells were not detectable. The prevalence of both VEGF-A- and N-cadherin-positive cells in the sample with FGF9-positive cells were significantly higher in comparison to FGF9-negative cases.
CONCLUSION: FGF9 can be associated with epithelial-to-mesenchymal transition and invasion by inducing VEGF-A expression in prostate cancer cells.

Entities:  

Keywords:  FGF9; N-cadherin; VEGF-A; biochemical recurrence; epithelial-mesenchymal transition; prostate cancer; radical prostatectomy

Mesh:

Substances:

Year:  2014        PMID: 24511001

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.

Authors:  J Liu; P You; G Chen; X Fu; X Zeng; C Wang; Y Huang; L An; X Wan; N Navone; C-L Wu; W L McKeehan; Z Zhang; W Zhong; F Wang
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

2.  Predicting associations between microRNAs and target genes in breast cancer by bioinformatics analyses.

Authors:  Tianying Zheng; Xing Zhang; Yonggang Wang; Xiucui Yu
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 3.  FGFs: crucial factors that regulate tumour initiation and progression.

Authors:  Qian Jing; Yuanyuan Wang; Hao Liu; Xiaowei Deng; Lin Jiang; Rui Liu; Haixing Song; Jingyi Li
Journal:  Cell Prolif       Date:  2016-07-07       Impact factor: 6.831

4.  Application of VEGFA and FGF-9 enhances angiogenesis, osteogenesis and bone remodeling in type 2 diabetic long bone regeneration.

Authors:  Christoph Wallner; Jessica Schira; Johannes Maximilian Wagner; Matthias Schulte; Sebastian Fischer; Tobias Hirsch; Wiltrud Richter; Stephanie Abraham; Ulrich Kneser; Marcus Lehnhardt; Björn Behr
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

5.  Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression.

Authors:  Yanqing Huang; Chengliu Jin; Tomoaki Hamana; Junchen Liu; Cong Wang; Lei An; Wallace L McKeehan; Fen Wang
Journal:  Int J Biol Sci       Date:  2015-06-11       Impact factor: 6.580

6.  Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.

Authors:  Yongjun Yin; Xiaodi Ren; Craig Smith; Qianxu Guo; Maria Malabunga; Ilhem Guernah; Yiwei Zhang; Juqun Shen; Haijun Sun; Nabil Chehab; Nick Loizos; Dale L Ludwig; David M Ornitz
Journal:  Dis Model Mech       Date:  2016-04-07       Impact factor: 5.758

Review 7.  Fibroblast Growth Factor Family in the Progression of Prostate Cancer.

Authors:  Jun Teishima; Tetsutaro Hayashi; Hirotaka Nagamatsu; Koichi Shoji; Hiroyuki Shikuma; Ryoken Yamanaka; Yohei Sekino; Keisuke Goto; Shogo Inoue; Akio Matsubara
Journal:  J Clin Med       Date:  2019-02-04       Impact factor: 4.241

Review 8.  Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.

Authors:  Harriet R Ferguson; Michael P Smith; Chiara Francavilla
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

9.  CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.

Authors:  Thomas A Werner; Christina M Forster; Levent Dizdar; Pablo E Verde; Katharina Raba; Matthias Schott; Wolfram T Knoefel; Andreas Krieg
Journal:  Br J Cancer       Date:  2017-11-07       Impact factor: 7.640

10.  CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.

Authors:  Thomas Artur Werner; Christina Maria Forster; Levent Dizdar; Pablo Emilio Verde; Katharina Raba; Matthias Schott; Wolfram Trudo Knoefel; Andreas Krieg
Journal:  J Cancer       Date:  2018-02-27       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.